Literature DB >> 22591220

High-dose, ten-day esomeprazole, amoxicillin and metronidazole triple therapy achieves high Helicobacter pylori eradication rates.

J Sánchez-Delgado1, P García-Iglesias, M Castro-Fernández, F Bory, M Barenys, L Bujanda, J Lisozain, M M Calvo, S Torra, J P Gisbert, X Calvet.   

Abstract

BACKGROUND: Strong acid inhibition using esomeprazole increases cure rates with triple therapy and 10-day treatments are more effective than 7-day ones. The combination of amoxicillin plus metronidazole at full doses, and using a physiologically-correct schedule three times a day, and has been shown to overcome metronidazole resistance and to achieve good eradication rates. AIMS: To assess the eradication rate of a new first-line treatment regimen associating strong acid inhibition, amoxicillin and metronidazole and to evaluate tolerance.
METHODS: Patients from eight hospitals were included. Helicobacter pylori status was assessed by at least one of the following: histology, culture, rapid urease test or urea breath test (UBT). Ten-day treatment was prescribed comprising esomeprazole 40 mg twice a day plus amoxicillin 1 g and metronidazol 500 mg both three times a day. Helicobacter pylori cure was assessed by UBT.
RESULTS: A hundred and thirty-six patients were enrolled. Mean age was 52.6 ± 16 years and 59.6% of patients were men. Main indications for treatment were: uninvestigated dyspepsia (13.6%); functional dyspepsia (18.2%); gastric ulcer (21.8%); and duodenal ulcer (39.8%). Helicobacter pylori eradication was achieved in 112 of the 127 patients who returned for follow-up. Eradication rates were 82.4% (95% CI: 74.7-88.1) by intention-to-treat analysis and 88.2% (95% CI: 81.2-92.8) by per protocol. Treatment was well tolerated and no major side effects were reported. Nine patients complained of mild side effects.
CONCLUSIONS: Cure rates of the combination of esomeprazole, amoxicillin and metronidazole are high and the treatment was well tolerated. This pilot study warrants the comparison of this schedule with current standards.
© 2012 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22591220     DOI: 10.1111/j.1365-2036.2012.05137.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  10 in total

1.  Management of Helicobacter pylori infection in Latin America: a Delphi technique-based consensus.

Authors:  Antonio Rollan; Juan Pablo Arab; M Constanza Camargo; Roberto Candia; Paul Harris; Catterina Ferreccio; Charles S Rabkin; Juan Cristóbal Gana; Pablo Cortés; Rolando Herrero; Luisa Durán; Apolinaria García; Claudio Toledo; Alberto Espino; Nicole Lustig; Alberto Sarfatis; Catalina Figueroa; Javier Torres; Arnoldo Riquelme
Journal:  World J Gastroenterol       Date:  2014-08-21       Impact factor: 5.742

2.  Current Paradigm and Future Directions for Treatment of Helicobacter pylori Infection.

Authors:  Jason Ferreira; Steven F Moss
Journal:  Curr Treat Options Gastroenterol       Date:  2014-12

Review 3.  Approach to Helicobacter pylori infection in geriatric population.

Authors:  Sevdenur Cizginer; Zehra Ordulu; Abdurrahman Kadayifci
Journal:  World J Gastrointest Pharmacol Ther       Date:  2014-08-06

Review 4.  Helicobacter pylori: future perspectives in therapy reflecting three decades of experience.

Authors:  Tajana Filipec Kanizaj; Nino Kunac
Journal:  World J Gastroenterol       Date:  2014-01-21       Impact factor: 5.742

Review 5.  Treatment of Helicobacter pylori infection: Current and future insights.

Authors:  Maliheh Safavi; Reyhaneh Sabourian; Alireza Foroumadi
Journal:  World J Clin Cases       Date:  2016-01-16       Impact factor: 1.337

6.  High-dose esomeprazole and amoxicillin dual therapy for first-line Helicobacter pylori eradication: a proof of concept study.

Authors:  Angelo Zullo; Lorenzo Ridola; Vincenzo De Francesco; Luigi Gatta; Cesare Hassan; Domenico Alvaro; Annamaria Bellesia; Germana de Nucci; Gianpiero Manes
Journal:  Ann Gastroenterol       Date:  2015 Oct-Dec

7.  A comparative study of the effect of 10-day esomeprazole containing levofloxacin versus clarithromycin sequential regimens on the treatment of Iranian patients with Helicobacter pylori infection.

Authors:  Marjan Mokhtare; Mehdi Nikkhah; Behdad Behnam; Shahram Agah; Mansour Bahardoust; Mohsen Masoodi; Amirhosein Faghihi
Journal:  Indian J Pharmacol       Date:  2020 Jul-Aug       Impact factor: 1.200

8.  Meta-analysis: High-dose vs. low-dose metronidazole-containing therapies for Helicobacter pylori eradication treatment.

Authors:  Yingjie Ji; Hong Lu
Journal:  PLoS One       Date:  2018-01-25       Impact factor: 3.240

9.  Effectiveness of Helicobacter pylori eradication established on the basis of examination of antibiotic resistance of the bacteria.

Authors:  Aleksander Szadkowski; Magdalena Zemlak; Jacek Muszyński
Journal:  Prz Gastroenterol       Date:  2018-05-16

10.  Chaperone activity of serine protease HtrA of Helicobacter pylori as a crucial survival factor under stress conditions.

Authors:  Urszula Zarzecka; Aileen Harrer; Anna Zawilak-Pawlik; Joanna Skorko-Glonek; Steffen Backert
Journal:  Cell Commun Signal       Date:  2019-12-03       Impact factor: 5.712

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.